Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The association between impulsivity and alcohol/drug use among prison inmates.

Bernstein MH, McSheffrey SN, van den Berg JJ, Vela JE, Stein LA, Roberts MB, Martin RA, Clarke JG.

Addict Behav. 2015 Mar;42:140-3. doi: 10.1016/j.addbeh.2014.11.016. Epub 2014 Nov 23.

2.

Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.

Murakami E, Wang T, Babusis D, Lepist EI, Sauer D, Park Y, Vela JE, Shih R, Birkus G, Stefanidis D, Kim CU, Cho A, Ray AS.

Antimicrob Agents Chemother. 2014;58(4):1943-51. doi: 10.1128/AAC.02350-13. Epub 2014 Jan 13.

3.

Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides.

Arnold JJ, Sharma SD, Feng JY, Ray AS, Smidansky ED, Kireeva ML, Cho A, Perry J, Vela JE, Park Y, Xu Y, Tian Y, Babusis D, Barauskus O, Peterson BR, Gnatt A, Kashlev M, Zhong W, Cameron CE.

PLoS Pathog. 2012;8(11):e1003030. doi: 10.1371/journal.ppat.1003030. Epub 2012 Nov 15.

4.

Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.

Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, Feng JY, Ray AS, Kim CU.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7. doi: 10.1016/j.bmcl.2012.02.105. Epub 2012 Mar 8.

PMID:
22446091
5.

Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.

Mackman RL, Ray AS, Hui HC, Zhang L, Birkus G, Boojamra CG, Desai MC, Douglas JL, Gao Y, Grant D, Laflamme G, Lin KY, Markevitch DY, Mishra R, McDermott M, Pakdaman R, Petrakovsky OV, Vela JE, Cihlar T.

Bioorg Med Chem. 2010 May 15;18(10):3606-17. doi: 10.1016/j.bmc.2010.03.041. Epub 2010 Mar 27.

PMID:
20409721
6.

Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.

Durand-Gasselin L, Van Rompay KK, Vela JE, Henne IN, Lee WA, Rhodes GR, Ray AS.

Mol Pharm. 2009 Jul-Aug;6(4):1145-51. doi: 10.1021/mp900036s.

7.

Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.

Boojamra CG, Parrish JP, Sperandio D, Gao Y, Petrakovsky OV, Lee SK, Markevitch DY, Vela JE, Laflamme G, Chen JM, Ray AS, Barron AC, Sparacino ML, Desai MC, Kim CU, Cihlar T, Mackman RL.

Bioorg Med Chem. 2009 Feb 15;17(4):1739-46. doi: 10.1016/j.bmc.2008.12.028. Epub 2008 Dec 24.

PMID:
19179082
8.

Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.

Cihlar T, Laflamme G, Fisher R, Carey AC, Vela JE, Mackman R, Ray AS.

Antimicrob Agents Chemother. 2009 Jan;53(1):150-6. doi: 10.1128/AAC.01183-08. Epub 2008 Nov 10.

9.

Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.

Vela JE, Miller MD, Rhodes GR, Ray AS.

Antivir Ther. 2008;13(6):789-97.

PMID:
18839780
10.

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

Cihlar T, Ray AS, Boojamra CG, Zhang L, Hui H, Laflamme G, Vela JE, Grant D, Chen J, Myrick F, White KL, Gao Y, Lin KY, Douglas JL, Parkin NT, Carey A, Pakdaman R, Mackman RL.

Antimicrob Agents Chemother. 2008 Feb;52(2):655-65. Epub 2007 Dec 3.

11.

Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.

Ray AS, Vela JE, Boojamra CG, Zhang L, Hui H, Callebaut C, Stray K, Lin KY, Gao Y, Mackman RL, Cihlar T.

Antimicrob Agents Chemother. 2008 Feb;52(2):648-54. Epub 2007 Dec 3.

12.

Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, Roy A, Rhodes GR.

Antivir Ther. 2007;12(2):267-72.

PMID:
17503669
13.

Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2'-deoxyadenosine triphosphate by ion-pairing LC/MS/MS.

Vela JE, Olson LY, Huang A, Fridland A, Ray AS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):335-43. Epub 2006 Nov 13.

PMID:
17101307
14.

Mechanism of active renal tubular efflux of tenofovir.

Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR.

Antimicrob Agents Chemother. 2006 Oct;50(10):3297-304.

15.

In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.

Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD.

Antivir Ther. 2006;11(3):377-84.

PMID:
16759055
16.

Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.

Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, Miller MD, Fridland A.

Antivir Ther. 2005;10(3):451-7.

PMID:
15918336
17.

Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells.

Ray AS, Vela JE, Olson L, Fridland A.

Biochem Pharmacol. 2004 Nov 1;68(9):1825-31.

PMID:
15450948
18.

[Value of echocardiography in the diagnosis of myxoma of the left auricle].

Alvarez del Puerto H, Lee H, Sasse L, Levinson I, Sklar H, Steiner LE, Vela JE.

Arch Inst Cardiol Mex. 1978 May-Jun;48(3):667-9. Spanish.

PMID:
697463
19.

Takayasu's arteritis. Clinical study of 107 cases.

Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE.

Am Heart J. 1977 Jan;93(1):94-103.

PMID:
12655
20.

[Editorial: What do we know about the risk factors in coronary cardiopathy? What can be done to prevent this suffering?].

Galland F, Vela JE.

Arch Inst Cardiol Mex. 1975 May-Jun;45(3):259-62. Spanish. No abstract available.

PMID:
1156000
21.

[Malpositions of the heart].

Vela JE.

G Ital Cardiol. 1975;5(6):811-5. English, Italian. No abstract available.

PMID:
1222878
22.

Acyanotic levoversion in situs inversus.

Attie F, Malpartida F, Poveda JJ, Testelli MR, Vela JE.

Chest. 1973 Nov;64(5):668-70. No abstract available.

PMID:
4796053
23.

[Truncus arteriosus communis: study of 14 cases].

Celemín LP, Vela JE.

Rev Esp Cardiol. 1971 Jul-Aug;24(4):237-45. Spanish. No abstract available.

PMID:
5156546
24.

[Complete post-operative auriculo-ventricular block in congenital heart diseases. Long-term development].

Brenes C, Osatinsky M, Cárdenas M, Vela JE.

Arch Inst Cardiol Mex. 1970 Jul-Aug;40(4):417-22. Spanish. No abstract available.

PMID:
5484310
25.

Rheumatic pulmonary valve disease.

Vela JE, Contreras R, Sosa FR.

Am J Cardiol. 1969 Jan;23(1):12-8. No abstract available.

PMID:
5380838
26.

[Transposition of the great vessels].

Vela JE.

Rass Clin Ter. 1966;65(1):1-21. Italian. No abstract available.

PMID:
5929641
27.

[Rheumatic mitral valve disease associated with atrial septal defect (Lutembacher disease) study of 12 cases, 8 and 4 clinical autopsy].

VELA JE, MATA LA, TORPEY A.

Arch Inst Cardiol Mex. 1957 Jul-Aug;27(4):411-50. Spanish. No abstract available.

PMID:
13471315
28.

[Five new cases of Ebstein's malformation with one operated case ending in exitus].

CALVO AM, FRAGA OC, ORDONEZ FG, VELA JE.

Arch Inst Cardiol Mex. 1956 Jan-Feb;26(1):67-107. Spanish. No abstract available.

PMID:
13355592

Supplemental Content

Support Center